By Research Area
Hot products 
-
Mouse Anti-B2M Recombinant Antibody (CBYY-0050) (CBMAB-0050-YY)
-
Mouse Anti-ACO2 Recombinant Antibody (V2-179329) (CBMAB-A0627-YC)
-
Mouse Anti-CD247 Recombinant Antibody (6B10.2) (CBMAB-C1583-YY)
-
Rat Anti-CCR2 Recombinant Antibody (475301) (CBMAB-C1338-LY)
-
Rabbit Anti-B2M Recombinant Antibody (CBYY-0059) (CBMAB-0059-YY)
-
Mouse Anti-ATG5 Recombinant Antibody (9H197) (CBMAB-A3945-YC)
-
Mouse Anti-CDK7 Recombinant Antibody (CBYY-C1783) (CBMAB-C3221-YY)
-
Mouse Anti-ENO2 Recombinant Antibody (H14) (CBMAB-E1341-FY)
-
Mouse Anti-14-3-3 Pan Recombinant Antibody (V2-9272) (CBMAB-1181-LY)
-
Mouse Anti-ACKR3 Recombinant Antibody (V2-261265) (CBMAB-C1023-LY)
-
Mouse Anti-CASQ1 Recombinant Antibody (CBFYC-0863) (CBMAB-C0918-FY)
-
Mouse Anti-CFL1 Recombinant Antibody (CBFYC-1771) (CBMAB-C1833-FY)
-
Mouse Anti-BIRC5 Recombinant Antibody (6E4) (CBMAB-CP2646-LY)
-
Mouse Anti-AAV9 Recombinant Antibody (V2-634029) (CBMAB-AP023LY)
-
Mouse Anti-C5B-9 Recombinant Antibody (CBFYA-0216) (CBMAB-X0304-FY)
-
Mouse Anti-DLG1 Monolconal Antibody (4F3) (CBMAB-0225-CN)
-
Mouse Anti-ADGRE2 Recombinant Antibody (V2-261270) (CBMAB-C0813-LY)
-
Mouse Anti-BHMT Recombinant Antibody (CBYY-0547) (CBMAB-0550-YY)
-
Mouse Anti-EIF4G1 Recombinant Antibody (2A9) (CBMAB-A2544-LY)
-
Mouse Anti-CTCF Recombinant Antibody (CBFYC-2371) (CBMAB-C2443-FY)
By Hallmark/Pathway
The progression from neoplastic transformation to metastatic dissemination is governed by the acquisition of specific biological capabilities—the hallmarks of cancer. These phenotypic alterations, ranging from sustained proliferative signaling to the evasion of immune destruction, are underpinned by profound dysregulation within intracellular kinase networks and transcriptional machinery. Contemporary research emphasizes the need to dissect these pathways not in isolation, but as integrated circuits that drive tumor heterogeneity and therapeutic resistance.
Targeting these mechanisms requires tools of exceptional specificity. Whether investigating the "angiogenic switch" mediated by hypoxic gradients or delineating the epithelial-mesenchymal transition (EMT) axis that facilitates invasion, the fidelity of molecular detection is paramount. Our portfolio is systematically organized to address these critical research nodes, offering validated antibodies and assays designed to interrogate cell cycle checkpoints, apoptotic thresholds, vascular remodeling, and the immunosuppressive tumor microenvironment with high-resolution precision.
Browse by Hallmark/Pathway
Select a pathway to explore targets, antibodies, and validation data.
Loading...
Compare
